Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib + Topotecan/Cisplatin in Cervical Cancer
NCT01076400Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- May 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of adavosertib in Cervical Cancer (CC) (3 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate at 1 year, Dose Limiting Toxicities at 1 year and 1 more. Started May 2010; status: terminated.
02
Drugs
adavosertib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01076400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01076400.